keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell lung cancer side effects

keyword
https://www.readbyqxmd.com/read/28938637/the-loss-of-function-of-dna-methyltransferase-1-by-sirna-impairs-the-growth-of-non-small-cell-lung-cancer-with-alleviated-side-effects-via-reactivation-of-rassf1a-and-apc-in-vitro-and-vivo
#1
Qi Lai, Yin-Hui Xu, Qiang Chen, Liang Tang, An-Gui Li, Li-Fei Zhang, Chun-Fang Zhang, Jian-Fei Song, Zhen-Zong Du
Hypermethylation of tumor suppressor genes (TSGs) promoters by DNA methyltransferase (DNMT) can be observed in almost all cancers which represent a hallmark of carcinogenesis, including lung cancer. DNMT inhibitors (e.g.5-Aza-CR/CdR) reactivate TSGs to exert anti-cancer activity and have been applied into the clinical. However, it is cytotoxic even at low concentrations, which might be not directly related to DNA methylation. We here investigated an alternative strategy in the lung cancer therapy and aimed to estimate and compare its efficiency and side effects of knockdown of DNMT1 in vitro and in vivo...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28915692/biomarker-analysis-of-the-phase-3-torch-trial-for-first-line-erlotinib-versus-chemotherapy-in-advanced-non-small-cell-lung-cancer-patients
#2
Lucia Kim, Mauro Saieg, Massimo Di Maio, Ciro Gallo, Charles Butts, Fortunato Ciardiello, Ronald Feld, Dengxiao Cheng, Vittorio Gebbia, Marco Angelo Burgio, Yasmin Alam, Simona Signoriello, Antonio Rossi, Natasha Leighl, Paolo Maione, Alessandro Morabito, Geoffrey Liu, Ming-Sound Tsao, Francesco Perrone, Cesare Gridelli
BACKGROUND: The TORCH phase III trial compared the efficacy of first-line erlotinib followed by chemotherapy at progression (experimental arm) with the reverse sequence (standard arm) in unselected advanced non-small cell lung cancer (NSCLC) patients. Here we report biomarker analyses. METHODS: EGFR and KRAS mutation, expression of EGFR family members and of cMET and PTEN and EGFR and ABCG2 germline polymorphisms were tested on tumor tissue or blood samples to either confirm previously proposed predictive role or describe it in an explorative setting...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28912410/-psoriasis-and-psoriatic-arthritis-induced-by-nivolumab-in-a-patient-with-advanced-non-small-cell-lung-cancer
#3
Yasoo Sugiura, Hiroyuki Fujimoto, Munehiro Yamamoto, Hisashi Nomura, Toshinori Hashizume, Osamu Kawai, Norito Araki, Kotaro Kawakami, Hitoshi Sueki, Hisae Fusegawa, Yasuyuki Ohkubo, Etsuo Nemoto
BACKGROUND: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-relatedad verse events. CASE PRESENTATION: A 66-year-oldman without any history of autoimmune disease was referredto our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage III A non-small-cell lung cancer by using bronchoscopic biopsy, computedtomography, andFDG -PET. After a single course of cisplatin andpemetrexed , the tumor size increasedremarkably andthe regimen was changedto nivolumab(3mg/kg every 2 weeks)...
September 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28911085/a-randomized-open-label-multicenter-phase-3-study-to-compare-the-efficacy-and-safety-of-eribulin-to-treatment-of-physician-s-choice-in-patients-with-advanced-non-small-cell-lung-cancer
#4
N Katakami, E Felip, D R Spigel, J-H Kim, M Olivo, M Guo, H Nokihara, J C-H Yang, N Iannotti, M Satouchi, F Barlesi
Background: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician's choice (TPC). Patients and methods: Patients with advanced NSCLC who had received ≥2 prior therapies, including platinum-based doublet and epidermal growth factor receptor tyrosine kinase inhibitor, were randomly assigned to receive eribulin or TPC (gemcitabine, pemetrexed, vinorelbine, docetaxel)...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28910804/ebus-tbna-can-distinguish-sarcoid-like-side-effect-of-nivolumab-treatment-from-tumor-progression-in-non-small-cell-lung-cancer
#5
Ségolène Lainez, Claire Tissot, Michèle Cottier, Jean-Michel Vergnon
With the expansion of immunotherapy in the treatment of lung cancer, clinicians have to face new clinical pictures and adapt their practice. We report the case of a 69-year-old man diagnosed with non-small cell lung cancer using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and treated with nivolumab as second-line therapy. After 8 injections of nivolumab, a new CT and PET scan revealed massive growth and increase in metabolism of hilar and mediastinal lymph nodes, whereas the size and metabolism of the left upper lobe lesion were reduced...
September 15, 2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/28900482/study-on-inhibitory-effect-of-maimendong-decoction-and-weijing-decoction-combination-with-cisplatin-on-nci-a549-xenograft-in-nude-mice-and-its-mechanism
#6
Fei Xiong, Miao Jiang, Meijuan Chen, Xiaoxia Wang, Shiping Zhang, Jing Zhou, Ke Li, Yan Sheng, Lian Yin, Yuping Tang, Lihong Ye, Mianhua Wu, Haian Fu, Xu Zhang
MaiMenDong Decoction and WeiJing Decoction (Jin formula) is a traditional Chinese medication that consists of 8 medicinal plants, which recorded in the classical TCM literature Jin Kui Yao Lue and has been utilized in the treatment of lung diseases for hundreds of years in China. The present study aimed to determine the anti-tumor activity and the underlying mechanisms of Jin formula combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC). Xenograft model of NCI-A549 was established in Balb/c nude mice...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28895421/in-vivo-isolation-of-circulating-tumor-cells-in-non-small-cell-lung-cancer-patients-by-cellcollector
#7
L Gasiorowski, W Dyszkiewicz, P Zielinski
In non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) can provide information on patient prognosis and treatment efficacy. Currently CTCs are mostly isolated in vitro from small volumes of patient blood samples. The aim of the study was to assess a medical device for in vivo isolation of CTCs directly from the blood of NSCLC patients. The device was inserted in a cubital vein through a standard cannula for thirty minutes. The interaction of target CTCs with the CellCollector was mediated by an antibody directed against the epithelial cell adhesion molecule...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28895417/the-prognostic-value-of-pre-treatment-thrombocytosis-in-two-cohorts-of-patients-with-non-small-cell-lung-cancer-treated-with-curatively-intended-chemoradiotherapy
#8
G Holgersson, S BergstrOm, A Hallqvist, P Liv, J Nilsson, L WillEn, J Nyman, S Ekman, R Henriksson, M Bergqvist
Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28875330/liposomes-co-loaded-with-6-phosphofructo-2-kinase-fructose-2-6-biphosphatase-3-pfkfb3-shrna-plasmid-and-docetaxel-for-the-treatment-of-non-small-cell-lung-cancer
#9
Nusrat Chowdhury, Imran Vhora, Ketan Patel, Ravi Doddapaneni, Arindam Mondal, Mandip Singh
PURPOSE: Non-small cell lung cancer is the leading cause of cancer related deaths globally. Considering the side effects and diminishing chemosensitivity to chemotherapy, novel treatment approaches are sought. Hence, we aim to develop a liposomal co-delivery system of pDNA expressing shRNA against PFKFB3 (pshPFKFB3) and docetaxel (DTX). METHODS: Cationic DTX liposomes complexed with pshPFKFB3 (PSH-DL) were developed. In vitro cell line studies were performed to evaluate transfection, PFKFB3 mRNA silencing, cytotoxicity, pGP inhibition, and protein markers expression...
September 5, 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28869399/clinical-applications-of-textural-analysis-in-non-small-cell-lung-cancer
#10
Iain Phillips, Mazhar Ajaz, Veni Ezhil, Vineet Prakash, Sheaka Alobaidli, Sarah J McQuaid, Christopher South, James Scuffham, Andrew Nisbet, Philip Evans
Lung cancer is the leading cause of cancer mortality worldwide. Treatment pathways include regular cross-sectional imaging, generating large data sets which present intriguing possibilities for exploitation beyond standard visual interpretation. This additional data mining has been termed 'radiomics' and includes semantic and agnostic approaches. Texture Analysis (TA) is an example of the latter, and uses a range of mathematically derived features to describe an image or region of an image. Often TA is used to describe a suspected or known tumour...
September 4, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28868009/good-tolerance-to-full-dose-crizotinib-in-a-patient-with-anaplastic-lymphoma-receptor-tyrosine-kinase-rearranged-lung-adenocarcinoma-and-preexisting-renal-impairment
#11
Adeline Rosoux, Fabrice Duplaquet, Sebahat Ocak
BACKGROUND: Crizotinib is an approved tyrosine kinase inhibitor in the treatment of advanced-stage non-small-cell lung cancer patients with anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement. Renal dysfunction after crizotinib administration was recently reported, but the physiopathological explanation and the safety in patients with preexisting renal dysfunction are still not clear. CASE PRESENTATION: A 44-year-old female and current smoker was diagnosed with a stage IV lung adenocarcinoma and treated with five lines of chemotherapy during a 4-year period of time...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28861738/a-surgical-case-of-radiotherapy-induced-esophageal-perforation-accompanying-pyogenic-spondylodiscitis-a-case-report
#12
Shuntaro Yoshimura, Kazuhiko Mori, Koichiro Kawasaki, Asami Tanabe, Susumu Aikou, Koichi Yagi, Masato Nishida, Hiroharu Yamashita, Sachiyo Nomura, Masayoshi Fukushima, Hideomi Yamashita, Yasuhiro Yamauchi, Yasuyuki Seto
BACKGROUND: Stereotactic body radiotherapy has been a treatment choice for lung cancer, especially in medically inoperable patients. However, the acute and late toxicity to adjacent organs have been reported as an uncommon but severe adverse effect. CASE PRESENTATION: A 65-year-old male was presented with his back pain and pyrexia. He had been followed up for non-small-cell lung cancer, which was treated by the stereotactic body radiotherapy 4 years prior to the current visit...
August 31, 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28836581/ginsenosides-synergize-with-mitomycin-c-in-combating-human-non-small-cell-lung-cancer-by-repressing-rad51-mediated-dna-repair
#13
Min Zhao, Dan-Dan Wang, Yuan Che, Meng-Qiu Wu, Qing-Ran Li, Chang Shao, Yun Wang, Li-Juan Cao, Guang-Ji Wang, Hai-Ping Hao
The use of ginseng extract as an adjuvant for cancer treatment has been reported in both animal models and clinical applications, but its molecular mechanisms have not been fully elucidated. Mitomycin C (MMC), an anticancer antibiotic used as a first- or second-line regimen in the treatment for non-small cell lung carcinoma (NSCLC), causes serious adverse reactions when used alone. Here, by using both in vitro and in vivo experiments, we provide evidence for an optimal therapy for NSCLC with total ginsenosides extract (TGS), which significantly enhanced the MMC-induced cytotoxicity against NSCLC A549 and PC-9 cells in vitro when used in combination with relatively low concentrations of MMC...
August 24, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28829490/effect-of-alk-inhibitors-in-the-treatment-of-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#14
G Li, W-R Dai, F-C Shao
OBJECTIVE: Lung cancer is the leading cause of cancer-related mortality. Over 80% of all lung cancer cases are non-small-cell lung cancer (NSCLC) and approximately 5% of NSCLC patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4 (EML4). NSCLC patients with positive ALK-EML4 gene fusion are highly sensitive to ALK-inhibitors. While the efficacy of the ALK-inhibitors in the treatment of NSCLC has been consistently reported, a limited number of randomized, large-scale clinical trials have been reported...
August 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28819411/comprehensive-study-of-prognostic-risk-factors-of-patients-underwent-pneumonectomy
#15
Chang Gu, Rui Wang, Xufeng Pan, Qingyuan Huang, Jizhuang Luo, Jiajie Zheng, Yiyang Wang, Jianxin Shi, Haiquan Chen
Introduction: To investigate postoperative complications and the prognostic risk factors of patients underwent pneumonectomy. Methods: Four hundred and six patients underwent pneumonectomy were subjected to the study. All the clinicopathologic data including age, gender, smoking history, surgical treatment, postoperative complications, tumor staging and the follow-up information were investigated. Results: The 30-day and 90-day mortality rates were 3.2% and 6.2%, respectively. Postoperative complications developed in 149 patients (36...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28812120/risk-adapted-robotic-stereotactic-body-radiation-therapy-for-inoperable-early-stage-non-small-cell-lung-cancer
#16
Susanne Temming, Martin Kocher, Erich Stoelben, Lars Hagmeyer, De-Hua Chang, Konrad Frank, Khosro Hekmat, Juergen Wolf, Wolfgang W Baus, Robert Semrau, Christian Baues, S Marnitz
PURPOSE: To evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients. METHODS: From 2012 to 2016, 106 patients (median age 74 years, range 50-94 years) with primary NSCLC were treated with SBRT using CyberKnife®. Histologic confirmation was available in 87 patients (82%). For mediastinal staging, 92 patients (87%) underwent (18)F-fluorodeoxyglucose positron-emission tomography (18-FDG-PET) and/or endobronchial ultrasound (EBUS)-guided lymph node biopsy or mediastinoscopy...
August 15, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28809468/construction-of-a-supramolecular-drug-drug-delivery-system-for-non-small-cell-lung-cancer-therapy
#17
Zhihao Zhang, Leilei Shi, Chenwei Wu, Yue Su, Jiwen Qian, Hongping Deng, Xinyuan Zhu
Nanoscale drug delivery systems (DDSs) are generally considered to be an effective alternative to small molecular chemotherapeutics due to improved accumulation in the tumor site and enhanced retention in blood. Nevertheless, most DDSs have low loading efficiency or even pose a high threat to normal organs from severe side effects. Ideally, a supramolecular drug-drug delivery system (SDDDS) composed of pure drugs via supramolecular interaction provides a hopeful approach for cancer treatment. Herein we propose a facile method to construct SDDDS via coassembly of gefitinib (GEF) and tripeptide tyroservatide (YSV), two kinds of chemotherapeutic pharmaceuticals for non-small-cell lung cancer (NSCLC) via multiple intermolecular interactions, including hydrogen bonding and π-π stacking...
August 25, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28794371/successful-treatment-with-alectinib-for-choroidal-metastasis-in-anaplastic-lymphoma-kinase-rearranged-non-small-cell-lung-cancer
#18
Tomoko Funazo, Kyohei Morita, Naoya Ikegami, Chisato Konishi, Satoshi Nakao, Ryo Ariyasu, Masato Taki, Kazuhiko Nakagawa, Moon Hee Hwang, Chie Yoshimura, Toshiaki Wakayama, Yasuo Nishizaka
Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life. In non-small cell lung cancer (NSCLC), targeted therapy against actionable driver mutations has gradually replaced radiotherapy as the treatment of choice for choroidal metastasis. Recently, there have been several case reports of choroidal metastasis in patients with anaplastic lymphoma kinase (ALK)-rearranged NSCLC. We herein report the case of a 40-year-old Japanese woman diagnosed with choroidal metastasis of an ALK-rearranged NSCLC who received alectinib as the first-line chemotherapy...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28769793/in-metastatic-non-small-cell-lung-cancer-platinum-based-treated-patients-herbal-treatment-improves-the-quality-of-life-a-prospective-randomized-controlled-clinical-trial
#19
Huiru Guo, Jia X Liu, Hegen Li, Jan P A Baak
Background: According to clinical experience, Traditional Chinese Medicine (TCM) herbs added to platinum-based therapy (PBT) improve the Quality of Life (QOL) in metastatic non-small cell lung cancer (NSCLC) patients, but this must be prospectively validated. Patients and Methods: Based on clinical impressions regarding the effect of adding TCM herbs to platinum-based chemotherapy, we anticipated that 2 × 21 patients would be sufficient to obtain significant results with an α < 0.05 and power (1 - β) of 90%...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28760151/pureair-protocol-randomized-controlled-trial-of-intensive-pulmonary-rehabilitation-versus-standard-care-in-patients-undergoing-surgical-resection-for-lung-cancer
#20
Stefania Fugazzaro, Stefania Costi, Carlotta Mainini, Besa Kopliku, Cristian Rapicetta, Roberto Piro, Roberta Bardelli, Patricia Filipa Sobral Rebelo, Carla Galeone, Giorgio Sgarbi, Filippo Lococo, Massimiliano Paci, Tommaso Ricchetti, Silvio Cavuto, Domenico Franco Merlo, Sara Tenconi
BACKGROUND: Non-small cell lung cancer is the most common type of lung cancer. Surgery is proven to be the most effective treatment in early stages, despite its potential impact on quality of life. Pulmonary rehabilitation, either before or after surgery, is associated with reduced morbidity related symptoms and improved exercise capacity, lung function and quality of life. METHODS: We describe the study protocol for the open-label randomized controlled trial we are conducting on patients affected by primary lung cancer (stages I-II) eligible for surgical treatment...
July 31, 2017: BMC Cancer
keyword
keyword
3577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"